| UCHL5 promotes hepatocellular carcinoma progression by promoting glycolysis through activating Wnt/beta-catenin pathway. | UCHL5 promotes hepatocellular carcinoma progression by promoting glycolysis through activating Wnt/β-catenin pathway.
Wan B, Cheng M, He T, Zhang L., Free PMC Article | 05/29/2024 |
| The TGF-beta/UCHL5/Smad2 Axis Contributes to the Pathogenesis of Placenta Accreta. | The TGF-β/UCHL5/Smad2 Axis Contributes to the Pathogenesis of Placenta Accreta.
Hashimoto K, Miyagawa Y, Watanabe S, Takasaki K, Nishizawa M, Yatsuki K, Takahashi Y, Kamata H, Kihira C, Hiraike H, Sasamori Y, Kido K, Ryo E, Nagasaka K., Free PMC Article | 10/6/2023 |
| MAFG-AS1/MAFG positive feedback loop contributes to cisplatin resistance in bladder urothelial carcinoma through antagonistic ferroptosis. | MAFG-AS1/MAFG positive feedback loop contributes to cisplatin resistance in bladder urothelial carcinoma through antagonistic ferroptosis.
Xiang L, Zeng Q, Liu J, Xiao M, He D, Zhang Q, Xie D, Deng M, Zhu Y, Liu Y, Bo H, Liu X, Zhou M, Xiong W, Zhou Y, Zhou J, Li X, Cao K. | 01/28/2023 |
| Deubiquitinase UCHL5 stabilizes ELK3 to potentiate cancer stemness and tumor progression in pancreatic adenocarcinoma (PAAD). | Deubiquitinase UCHL5 stabilizes ELK3 to potentiate cancer stemness and tumor progression in pancreatic adenocarcinoma (PAAD).
Yang Y, Cao L, Guo Z, Gu H, Zhang K, Qiu Z. | 12/3/2022 |
| A ubiquitinome analysis to study the functional roles of the proteasome associated deubiquitinating enzymes USP14 and UCH37. | A ubiquitinome analysis to study the functional roles of the proteasome associated deubiquitinating enzymes USP14 and UCH37.
van der Wal L, Bezstarosti K, Demmers JAA. | 05/28/2022 |
| UCHL5 controls beta-catenin destruction complex function through Axin1 regulation. | UCHL5 controls β-catenin destruction complex function through Axin1 regulation.
Han W, Koo Y, Chaieb L, Keum BR, Han JK., Free PMC Article | 04/30/2022 |
| Deubiquitination and Activation of the NLRP3 Inflammasome by UCHL5 in HCV-Infected Cells. | Deubiquitination and Activation of the NLRP3 Inflammasome by UCHL5 in HCV-Infected Cells.
Ramachandran A, Kumar B, Waris G, Everly D., Free PMC Article | 01/22/2022 |
| Ubiquitin Carboxyl-Terminal Hydrolases (UCHs): Potential Mediators for Cancer and Neurodegeneration. | Ubiquitin Carboxyl-Terminal Hydrolases (UCHs): Potential Mediators for Cancer and Neurodegeneration.
Sharma A, Liu H, Tobar-Tosse F, Chand Dakal T, Ludwig M, Holz FG, Loeffler KU, Wüllner U, Herwig-Carl MC., Free PMC Article | 04/3/2021 |
| LncRNA DRAIC inhibits proliferation and metastasis of gastric cancer cells through interfering with NFRKB deubiquitination mediated by UCHL5. | LncRNA DRAIC inhibits proliferation and metastasis of gastric cancer cells through interfering with NFRKB deubiquitination mediated by UCHL5.
Zhang Z, Hu X, Kuang J, Liao J, Yuan Q., Free PMC Article | 02/27/2021 |
| Proteasome-Bound UCH37/UCHL5 Debranches Ubiquitin Chains to Promote Degradation. | Proteasome-Bound UCH37/UCHL5 Debranches Ubiquitin Chains to Promote Degradation.
Deol KK, Crowe SO, Du J, Bisbee HA, Guenette RG, Strieter ER., Free PMC Article | 12/19/2020 |
| Impact of Losing hRpn13 Pru or UCHL5 on Proteasome Clearance of Ubiquitinated Proteins and RA190 Cytotoxicity. | Impact of Losing hRpn13 Pru or UCHL5 on Proteasome Clearance of Ubiquitinated Proteins and RA190 Cytotoxicity.
Osei-Amponsa V, Sridharan V, Tandon M, Evans CN, Klarmann K, Cheng KT, Lack J, Chari R, Walters KJ., Free PMC Article | 09/19/2020 |
| Data suggest that UCHL5 can deubiquitinate distinct substrates from that of USP14 at the proteasome and regulate the ubiquitination of the proteasome itself which is tightly linked to its function. | Inactive USP14 and inactive UCHL5 cause accumulation of distinct ubiquitinated proteins in mammalian cells.
Chadchankar J, Korboukh V, Conway LC, Wobst HJ, Walker CA, Doig P, Jacobsen SJ, Brandon NJ, Moss SJ, Wang Q., Free PMC Article | 03/28/2020 |
| UCH37 maintains the homeostasis of proteasomal degradation reciprocally by assisting the recruitment of the ubiquitin receptor Rpn13 into the proteasome and by reversing ubiquitination of certain critical substrates of the 26 S proteasome. | Proteasomal deubiquitinase UCH37 inhibits degradation of β-catenin and promotes cell proliferation and motility.
Li Z, Zhou L, Jiang T, Fan L, Liu X, Qiu X. | 08/10/2019 |
| Rpn13-Rpn2 complex structural analysis shows that RA190 targets hRpn13 and Uch37 through parallel mechanisms and at proteasomes, RA190-inactivated Uch37 cannot disassemble hRpn13-bound ubiquitin chains | Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets.
Lu X, Nowicka U, Sridharan V, Liu F, Randles L, Hymel D, Dyba M, Tarasov SG, Tarasova NI, Zhao XZ, Hamazaki J, Murata S, Burke TR Jr, Walters KJ., Free PMC Article | 12/22/2018 |
| Our study provides a new mechanism for chromatin occupancy of Tcf7 and uncovers the physiological significance of Uch37 during early vertebrate development by regulating the Wnt/beta-catenin pathway. | Ubiquitin C-terminal hydrolase37 regulates Tcf7 DNA binding for the activation of Wnt signalling.
Han W, Lee H, Han JK., Free PMC Article | 11/3/2018 |
| Our studies provide a molecular mechanism by which UCHL5 mitigates TGFbeta-1 signaling by stabilizing Smad2/Smad3. These data indicate that UCHL5 may contribute to the pathogenesis of idiopathic pulmonary fibrosis and may be a potential therapeutic target. | Ubiquitin carboxyl-terminal hydrolase-L5 promotes TGFβ-1 signaling by de-ubiquitinating and stabilizing Smad2/Smad3 in pulmonary fibrosis.
Nan L, Jacko AM, Tan J, Wang D, Zhao J, Kass DJ, Ma H, Zhao Y., Free PMC Article | 06/9/2018 |
| Positive cytoplasmic UCHL5 tumor immunoexpression is linked to increased survival of patients with small (<5 cm) tumors (p = 0.001), disease stages I-II (p = 0.025), and age 66 years or older (p = 0.037). UCHL5 is thus a potential marker in gastric cancer with new prognostic relevance. | Positive cytoplasmic UCHL5 tumor expression in gastric cancer is linked to improved prognosis.
Arpalahti L, Laitinen A, Hagström J, Mustonen H, Kokkola A, Böckelman C, Haglund C, Holmberg CI., Free PMC Article | 05/26/2018 |
| our report demonstrates significant value in targeting USP14/UCHL5 with VLX1570 in drug-resistant Waldenstrom macroglobulinemia (WM) and carries a high potential for clinical translation | Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.
Paulus A, Akhtar S, Caulfield TR, Samuel K, Yousaf H, Bashir Y, Paulus SM, Tran D, Hudec R, Cogen D, Jiang J, Edenfield B, Novak A, Ansell SM, Witzig T, Martin P, Coleman M, Roy V, Ailawadhi S, Chitta K, Linder S, Chanan-Khan A., Free PMC Article | 11/4/2017 |
| UCHL5 is a promising novel prognostic marker in lymph-node-positive rectal cancer. Our results also advance the currently limited knowledge of biomarkers in colorectal cancer treatment. | UCHL5 expression associates with improved survival in lymph-node-positive rectal cancer.
Arpalahti L, Hagström J, Mustonen H, Lundin M, Haglund C, Holmberg CI. | 07/29/2017 |
| UCHL5 expression could function as a prognostic marker in pancreatic ductal adenocarcinoma, particularly at disease stages IIB to III. As UCHL5 is one of the few markers predicting increased survival, our results may be of clinical relevance. | Nuclear ubiquitin C-terminal hydrolase L5 expression associates with increased patient survival in pancreatic ductal adenocarcinoma.
Arpalahti L, Saukkonen K, Hagström J, Mustonen H, Seppänen H, Haglund C, Holmberg CI. | 07/15/2017 |
| this work implicates hRpn13 and Uch37 in cell cycle progression, providing a rationale for their function in cellular proliferation and for the apoptotic effect of the hRpn13-targeting molecule RA190. | The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle Progression.
Randles L, Anchoori RK, Roden RB, Walters KJ., Free PMC Article | 10/8/2016 |
| These results uncover a novel mechanism for E2F1 transcriptional activation through removal of its Lys-63-linked ubiquitination by UCH37. | Regulation of E2 promoter binding factor 1 (E2F1) transcriptional activity through a deubiquitinating enzyme, UCH37.
Mahanic CS, Budhavarapu V, Graves JD, Li G, Lin WC., Free PMC Article | 02/6/2016 |
| Uch37 consists of two domains, a globular UCH-domain and a fibrous C-terminal tail. The C-terminal residues of Uch37 are implicated in Rpn13 binding. | Structural characterization of human Uch37.
Burgie SE, Bingman CA, Soni AB, Phillips GN Jr., Free PMC Article | 07/4/2015 |
| Data indicate that ubiquitin thioesterase L5 UCH37 (UCHL5) comprises a catalytic UCH domain followed by the four-helix (alpha8-alpha11) C-terminal domain. | Structural basis for the activation and inhibition of the UCH37 deubiquitylase.
Vander Linden RT, Hemmis CW, Schmitt B, Ndoja A, Whitby FG, Robinson H, Cohen RE, Yao T, Hill CP., Free PMC Article | 06/20/2015 |
| Data show that DEUBAD domain in RPN13 (ADRM1) activates ubiquitin thioesterase L5 (UCH-L5), and the related DEUBAD domain in INO80G (NFRKB) inhibits UCH-L5. | Mechanism of UCH-L5 activation and inhibition by DEUBAD domains in RPN13 and INO80G.
Sahtoe DD, van Dijk WJ, El Oualid F, Ekkebus R, Ovaa H, Sixma TK., Free PMC Article | 06/20/2015 |